Akinetic view of GPCR allostery and biased agonism

Nature Chemical Biology

Volumn 13, Issue 9, 2017, Pages 929-937

  Lane, J Robert ^a   May, Lauren T ^a   Parton, Robert G ^b   Sexton, Patrick M ^a   Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LIGAND;

AGONISTS; ALLOSTERISM; CHEMISTRY; DRUG DEVELOPMENT; KINETICS; MOLECULAR MODEL; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; DRUG DISCOVERY; KINETICS; LIGANDS; MODELS, MOLECULAR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 85027834609     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2431     Document Type: Review

References (97)

1. Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19-34 (2017).
2. Lefkowitz, R.J. & Shenoy, S.K. Transduction of receptor signals by β-arrestins. Science 308, 512-517 (2005).
3. Christopoulos, A. et al. International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. Pharmacol. Rev. 66, 918-947 (2014).
4. Keov, P., Sexton, P.M. & Christopoulos, A. Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology 60, 24-35 (2011).
5. Leff, P. The two-state model of receptor activation. Trends Pharmacol. Sci. 16, 89-97 (1995).
6. Samama, P., Cotecchia, S., Costa, T. & Lefkowitz, R.J. A mutation-induced activated state of the β 2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268, 4625-4636 (1993).
7. Kenakin, T. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol. Sci. 24, 346-354 (2003).
8. Canals, M. et al. A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation. J. Biol. Chem. 287, 650-659 (2012).
9. Shonberg, J. et al. Biased agonism at G protein-coupled receptors: the promise and the challenges-a medicinal chemistry perspective. Med. Res. Rev. 34, 1286-1330 (2014).
10. Kenakin, T. & Christopoulos, A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 12, 205-216 (2013).
11. Leach, K., Sexton, P.M. & Christopoulos, A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol. Sci. 28, 382-389 (2007).
12. Wootten, D., Christopoulos, A. & Sexton, P.M. Emerging paradigms in GPCR allostery: implications for drug discovery. Nat. Rev. Drug Discov. 12, 630-644 (2013).
13. Violin, J.D., Crombie, A.L., Soergel, D.G. & Lark, M.W. Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol. Sci. 35, 308-316 (2014).
14. Rominger, D.H., Cowan, C.L., Gowen-MacDonald, W. & Violin, J.D. Biased ligands: pathway validation for novel GPCR therapeutics. Curr. Opin. Pharmacol. 16, 108-115 (2014).
15. Huang, W. et al. Structural insights into μ-opioid receptor activation. Nature 524, 315-321 (2015).
16. Sounier, R. et al. Propagation of conformational changes during μ-opioid receptor activation. Nature 524, 375-378 (2015).
17. Rahmeh, R. et al. Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proc. Natl. Acad. Sci. USA 109, 6733-6738 (2012).
18. Granier, S., Kim, S., Fung, J.J., Bokoch, M.P. & Parnot, C. FRET-based measurement of GPCR conformational changes. Methods Mol. Biol. 552, 253-268 (2009).
19. Ghanouni, P. et al. Functionally different agonists induce distinct conformations in the G protein coupling domain of the β 2 adrenergic receptor. J. Biol. Chem. 276, 24433-24436 (2001).
20. Altenbach, C., Kusnetzow, A.K., Ernst, O.P., Hofmann, K.P. & Hubbell, W.L. High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation. Proc. Natl. Acad. Sci. USA 105, 7439-7444 (2008).
21. West, G.M. et al. Ligand-dependent perturbation of the conformational ensemble for the GPCR β2 adrenergic receptor revealed by HDX. Structure 19, 1424-1432 (2011).
22. Liu, J.J., Horst, R., Katritch, V., Stevens, R.C. & Wüthrich, K. Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science 335, 1106-1110 (2012).
23. Kahsai, A.W. et al. Multiple ligand-specific conformations of the β2-adrenergic receptor. Nat. Chem. Biol. 7, 692-700 (2011).
24. Lee, M.-H. et al. The conformational signature of β-arrestin2 predicts its trafficking and signalling functions. Nature 531, 665-668 (2016).
25. Nuber, S. et al. β-Arrestin biosensors reveal a rapid, receptor-dependent activation/deactivation cycle. Nature 531, 661-664 (2016).
26. Furness, S.G.B. et al. Ligand-dependent modulation of G protein conformation alters drug efficacy. Cell 167, 739-749.e11 (2016).
27. Kenakin, T. & Christopoulos, A. Analytical pharmacology: the impact of numbers on pharmacology. Trends Pharmacol. Sci. 32, 189-196 (2011).
28. Black, J.W., Leff, P., Shankley, N.P. & Wood, J. An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br. J. Pharmacol. 84, 561-571 (1985).
29. De Léan, A., Stadel, J.M. & Lefkowitz, R.J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J. Biol. Chem. 255, 7108-7117 (1980).
30. Ehlert, F.J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 33, 187-194 (1988).
31. Stockton, J.M., Birdsall, N.J., Burgen, A.S. & Hulme, E.C. Modification of the binding properties of muscarinic receptors by gallamine. Mol. Pharmacol. 23, 551-557 (1983).
32. Paton, W.D.M. A theory of drug action based on the rate of drug-receptor combination. Proc. Biol. Sci. 154, 21-69 (1961).
33. Waelbroeck, M., Boufrahi, L. & Swillens, S. Seven helix receptors are enzymes catalysing G protein activation. What is the agonist Kact? J. Theor. Biol. 187, 15-37 (1997).
34. Linderman, J.J. Modeling of G-protein-coupled receptor signaling pathways. J. Biol. Chem. 284, 5427-5431 (2009).
35. Kinzer-Ursem, T.L. & Linderman, J.J. Both ligand- and cell-specific parameters control ligand agonism in a kinetic model of g protein-coupled receptor signaling. PLoS Comput. Biol. 3, e6 (2007).
36. Jaakola, V.-P. et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322, 1211-1217 (2008).
37. Xu, F. et al. Structure of an agonist-bound human A2A adenosine receptor. Science 332, 322-327 (2011).
38. Rasmussen, S.G.F. et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477, 549-555 (2011).
39. Rasmussen, S.G.F. et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature 450, 383-387 (2007).
40. Haga, K. et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482, 547-551 (2012).
41. Kruse, A.C. et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504, 101-106 (2013).
42. DeVree, B.T. et al. Allosteric coupling from G protein to the agonist-binding pocket in GPCRs. Nature 535, 182-186 (2016).
43. Sykes, D.A., Dowling, M.R. & Charlton, S.J. Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol. Pharmacol. 76, 543-551 (2009).
44. Guo, D., Mulder-Krieger, T., Ijzerman, A.P. & Heitman, L.H. Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time. Br. J. Pharmacol. 166, 1846-1859 (2012).
45. Rosethorne, E.M. et al. Long receptor residence time of C26 contributes to super agonist activity at the human β2 adrenoceptor. Mol. Pharmacol. 89, 467-475 (2016).
46. Louvel, J. et al. Structure-kinetics relationships of Capadenoson derivatives as adenosine A1 receptor agonists. Eur. J. Med. Chem. 101, 681-691 (2015).
47. Klein Herenbrink, C. et al. The role of kinetic context in apparent biased agonism at GPCRs. Nat. Commun. 7, 10842 (2016).
48. Gentry, P.R., Sexton, P.M. & Christopoulos, A. Novel allosteric modulators of G protein-coupled receptors. J. Biol. Chem. 290, 19478-19488 (2015).
49. van der Westhuizen, E.T., Valant, C., Sexton, P.M. & Christopoulos, A. Endogenous allosteric modulators of G protein-coupled receptors. J. Pharmacol. Exp. Ther. 353, 246-260 (2015).
50. Christopoulos, A. & Kenakin, T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54, 323-374 (2002).
51. Motulsky, H.J. & Mahan, L.C. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol. Pharmacol. 25, 1-9 (1984).
52. Christopoulos, A. Advances in G protein-coupled receptor allostery: from function to structure. Mol. Pharmacol. 86, 463-478 (2014).
53. Lazareno, S., Popham, A. & Birdsall, N.J. Analogs of WIN 62, 577 define a second allosteric site on muscarinic receptors. Mol. Pharmacol. 62, 1492-1505 (2002).
54. Gao, Z.G. & Ijzerman, A.P. Allosteric modulation of A(2A) adenosine receptors by amiloride analogues and sodium ions. Biochem. Pharmacol. 60, 669-676 (2000).
55. Bruns, R.F. & Fergus, J.H. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. 38, 939-949 (1990).
56. Clark, A.L. & Mitchelson, F. The inhibitory effect of gallamine on muscarinic receptors. Br. J. Pharmacol. 58, 323-331 (1976).
57. Leach, K. et al. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 35, 855-869 (2010).
58. Thal, D.M. et al. Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. Nature 531, 335-340 (2016).
59. Kruse, A.C. et al. Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482, 552-556 (2012).
60. Dror, R.O. et al. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature 503, 295-299 (2013).
61. Dror, R.O. et al. Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc. Natl. Acad. Sci. USA 108, 13118-13123 (2011).
62. Nguyen, A.T.N. et al. Extracellular loop 2 of the adenosine A1 receptor has a key role in orthosteric ligand affinity and agonist efficacy. Mol. Pharmacol. 90, 703-714 (2016).
63. Proska, J. & Tucek, S. Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors. Mol. Pharmacol. 45, 709-717 (1994).
64. Avlani, V., May, L.T., Sexton, P.M. & Christopoulos, A. Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 308, 1062-1072 (2004).
65. Limbird, L.E., Meyts, P.D. & Lefkowitz, R.J. Beta-adrenergic receptors: evidence for negative cooperativity. Biochem. Biophys. Res. Commun. 64, 1160-1168 (1975).
66. Harikumar, K.G. et al. Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery. Proc. Natl. Acad. Sci. USA 109, 18607-18612 (2012).
67. May, L.T., Bridge, L.J., Stoddart, L.A., Briddon, S.J. & Hill, S.J. Allosteric interactions across native adenosine-A3 receptor homodimers: quantification using single-cell ligand-binding kinetics. FASEB J. 25, 3465-3476 (2011).
68. Kara, E., Lin, H. & Strange, P.G. Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics. J. Neurochem. 112, 1442-1453 (2010).
69. Urizar, E. et al. Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J. 24, 1954-1964 (2005).
70. Gupta, K. et al. The role of interfacial lipids in stabilizing membrane protein oligomers. Nature 541, 421-424 (2017).
71. Szabo, M., Klein Herenbrink, C., Christopoulos, A., Lane, J.R. & Capuano, B. Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D2 receptor. J. Med. Chem. 57, 4924-4939 (2014).
72. Tschammer, N., Bollinger, S., Kenakin, T. & Gmeiner, P. Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor. Mol. Pharmacol. 79, 575-585 (2011).
73. Charlton, S.J. & Vauquelin, G. Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays. Br. J. Pharmacol. 161, 1250-1265 (2010).
74. Unett, D.J. et al. Kinetics of 5-HT2B receptor signaling: profound agonist-dependent effects on signaling onset and duration. J. Pharmacol. Exp. Ther. 347, 645-659 (2013).
75. Wacker, D. et al. Structural features for functional selectivity at serotonin receptors. Science 340, 615-619 (2013).
76. Wang, C. et al. Structural basis for molecular recognition at serotonin receptors. Science 340, 610-614 (2013).
77. Shonberg, J. et al. A structure-activity analysis of biased agonism at the dopamine D2 receptor. J. Med. Chem. 56, 9199-9221 (2013).
78. Chen, X.-T. et al. Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl](2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl)amine (TRV130), for the treatment of acute severe pain. J. Med. Chem. 56, 8019-8031 (2013).
79. Baltos, J.-A. et al. Structure-activity analysis of biased agonism at the human adenosine A3 receptor. Mol. Pharmacol. 90, 12-22 (2016).
80. Hiller, C. et al. Functionally selective dopamine D2/D3 receptor agonists comprising an enyne moiety. J. Med. Chem. 56, 5130-5141 (2013).
81. Murphy, J.E., Padilla, B.E., Hasdemir, B., Cottrell, G.S. & Bunnett, N.W. Endosomes: a legitimate platform for the signaling train. Proc. Natl. Acad. Sci. USA 106, 17615-17622 (2009).
82. Irannejad, R. et al. Conformational biosensors reveal GPCR signalling from endosomes. Nature 495, 534-538 (2013).
83. Vilardaga, J.-P., Jean-Alphonse, F.G. & Gardella, T.J. Endosomal generation of cAMP in GPCR signaling. Nat. Chem. Biol. 10, 700-706 (2014).
84. Andreassen, K.V. et al. Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias. PLoS One 9, e92042 (2014).
85. Wacker, D. et al. Crystal structure of an LSD-bound human serotonin receptor. Cell 168, 377-389.e12 (2017).
86. Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A. & Novick, S. A simple method for quantifying functional selectivity and agonist bias. ACS Chem. Neurosci. 3, 193-203 (2012).
87. Ehlert, F.J. Analysis of allosterism in functional assays. J. Pharmacol. Exp. Ther. 315, 740-754 (2005).
88. Rajagopal, S. et al. Quantifying ligand bias at seven-transmembrane receptors. Mol. Pharmacol. 80, 367-377 (2011).
89. Strachan, R.T. et al. Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR). J. Biol. Chem. 289, 14211-14224 (2014).
90. Hall, D.A. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol. Pharmacol. 58, 1412-1423 (2000).
91. Copeland, R.A. The drug-target residence time model: a 10-year retrospective. Nat. Rev. Drug Discov. 15, 87-95 (2016).
92. Louvel, J. et al. Agonists for the adenosine A1 receptor with tunable residence time. A Case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines. J. Med. Chem. 57, 3213-3222 (2014).
93. Schneider, E.V., Böttcher, J., Huber, R., Maskos, K. & Neumann, L. Structure-kinetic relationship study of CDK8/CycC specific compounds. Proc. Natl. Acad. Sci. USA 110, 8081-8086 (2013).
94. Vauquelin, G. & Charlton, S.J. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br. J. Pharmacol. 161, 488-508 (2010).
95. Guo, D., Hillger, J.M., Ijzerman, A.P. & Heitman, L.H. Drug-target residence time-a case for G protein-coupled receptors. Med. Res. Rev. 34, 856-892 (2014).
96. Disse, B. et al. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 52, 537-544 (1993).
97. Seeman, P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin. Ther. Targets 10, 515-531 (2006).